@article{5933983a0ce9432787479cc0d1a55e0f,
title = "Comprehensive T cell repertoire characterization of non-small cell lung cancer",
abstract = "Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.",
author = "Alexandre Reuben and Jiexin Zhang and Chiou, {Shin Heng} and Gittelman, {Rachel M.} and Jun Li and Lee, {Won Chul} and Junya Fujimoto and Carmen Behrens and Xiaoke Liu and Feng Wang and Kelly Quek and Chunlin Wang and Farrah Kheradmand and Runzhe Chen and Chow, {Chi Wan} and Heather Lin and Chantale Bernatchez and Ali Jalali and Xin Hu and Wu, {Chang Jiun} and Eterovic, {Agda Karina} and Parra, {Edwin Roger} and Erik Yusko and Ryan Emerson and Sharon Benzeno and Marissa Vignali and Xifeng Wu and Yuanqing Ye and Little, {Latasha D.} and Curtis Gumbs and Xizeng Mao and Xingzhi Song and Samantha Tippen and Thornton, {Rebecca L.} and Tina Cascone and Alexandra Snyder and Wargo, {Jennifer A.} and Roy Herbst and Stephen Swisher and Humam Kadara and Cesar Moran and Neda Kalhor and Jianhua Zhang and Paul Scheet and Vaporciyan, {Ara A.} and Boris Sepesi and Gibbons, {Don L.} and Harlan Robins and Patrick Hwu and Heymach, {John V.} and Padmanee Sharma and Allison, {James P.} and Veera Baladandayuthapani and Lee, {Jack J.} and Davis, {Mark M.} and Wistuba, {Ignacio I.} and Futreal, {P. Andrew} and Jianjun Zhang",
note = "Funding Information: R.M.G, E.Y, R.E., S.B, M.V. and A.S. have employment and equity ownership with Adaptive Biotechnologies. J.A.W. has honoraria from speakers' bureau of Dava Oncology and is an advisory board member for GlaxoSmithKline and Roche/Genentech. H.R. has employment, equity ownership, patents, and royalties with Adaptive Biotechnologies. P.H. serves on the advisory board of Iovance Biotherapeutics, Inc. and Immatics US. J.V.H. is a consultant for AstraZeneca, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Medivation, ARIAD, Synta, Oncomed, Novartis, Genentech, and Calithera Biosciences, holds stock in Cardinal Spine LLC and Bio-Tree, and has received funding from AstraZeneca. P.S. is a consultant for Bristol-Myers Squibb, Jounce Therapeutics, Helsinn, and GlaxoSmithKline as well as a stockholder from Jounce Therapeutics. J.P.A. is a consultant and stockholder for Jounce Therapeutics, receives royalties from Bristol-Myers Squibb, and has intellectual property with Bristol-Myers Squibb and Merck. I.I.W. receives honoraria from Roche/Genentech, Ventana, GlaxoSmithKline, Celgene, Bristol-Myers Squibb, Synta Pharmaceuticals, Boehringer Ingelheim, Medscape, Clovis, Astra-Zeneca, and Pfizer, and research support from Roche/Genentech, Oncoplex, and HGT. All remaining authors report no conflicts of interest. Funding Information: This study was supported by the MD Anderson Lung Cancer Moon Shot Program, the Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award grant (RP160668), the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629-01), the AACR Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the Cancer Prevention and Research Institute of Texas (R120501), the MD Anderson Physician Scientist Program, the Khalifa Scholar Award, The University of Texas (UT) Systems Stars Award (PS100149), the Welch Foundation Robert A. Welch Distinguished University Chair Award (G-0040), a Department of Defense PROSPECT grant (W81XWH-07-1-0306), the UT Lung Specialized Programs of Research Excellence Grant (P50CA70907), the MD Anderson Cancer Center Support Grant (CA016672), MD Anderson Institutional Support for the Center for Translational and Public Health Genomics, the T.J. Martell Foundation, Adaptive Biotechnologies, the Parker Institute for Cancer Immunotherapy, the Howard Hughes Medical Institute and the Kimberley Clark Foundation Award for Scientific Achievement provided by MD Anderson{\textquoteright}s Odyssey Fellowship Program. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41467-019-14273-0",
language = "English (US)",
volume = "11",
journal = "Nature communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}